AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03130153
Drug: Aspirin Powder
RxNorm normalized name: ASPIRIN 500 mg in 1 g ORAL POWDER [Aspirin Powder]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.
Trial: NCT03130153
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
Trial: NCT04268927
Drug: GnRH ant
RxNorm normalized name: wood ant preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
Trial: NCT00622037
Drug: PEG-400 based artificial tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
Trial: NCT04301856
Drug: CFTR Modulators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFTR modulators as recommended in routine care by the french health authorities
Trial: NCT04953195
Drug: Levothyroxine Sodium Tablets
RxNorm normalized name: Levothyroxine Sodium Tablets
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
Trial: NCT00490230
Drug: WR 279396
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01526408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
Trial: NCT02549014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
Trial: NCT02402621
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl with antiemetic drug
Trial: NCT01646567
Drug: Placebo to SHP-141C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Cream
Trial: NCT01361191
Drug: R-MEGACHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~* If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3).
Trial: NCT00835900
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01719705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ninety minutes before surgery, the parturients receive two identical placebo capsules
Trial: NCT03981861
Drug: Metformin and Spironolactone
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
Trial: NCT03249753
Drug: SPH3127 200mg Panel A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
Trial: NCT03985371
Drug: EDTA Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in the Band Keratopathy affected eye only, two times per day for six months.
Trial: NCT03249753
Drug: SPH3127 200mg Panel B
RxNorm normalized name: benzocaine 200 MG/ML [Zilactin B]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
Trial: NCT02740712
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg (4 x 50mg) Tablet
Trial: NCT01412151
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
Trial: NCT01081626
Drug: Recombinant FSH (follitropin alpha)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
Trial: NCT00976872
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
Trial: NCT00215137
Drug: Placebo ( sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator in double.blind phase.
Trial: NCT04187807
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo
Trial: NCT02158052
Drug: Bone marrow transplant from a related donor
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor bone marrow (\> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
Trial: NCT01023607
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin,10mg/day
Trial: NCT00124787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO q 6 hours x 4 doses
Trial: NCT01775475
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01775475
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01775475
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02291029
Drug: CFZ533 placebo- Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses of placebo s.c. injection
Trial: NCT02291029
Drug: CFZ533 placebo - Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses of placebo intravenous infusion
Trial: NCT02488538
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: women will receive oral fluoxetine 20 mg daily
Trial: NCT02488538
Drug: Combined oral contraceptives placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
Trial: NCT02488538
Drug: Fluoxetine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
Trial: NCT04513652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Ophthalmic Solution
Trial: NCT03110354
Drug: DS-3201b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
Trial: NCT00388648
Drug: mixture of amino and keto acids
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02938572
Drug: NNC0143-0406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c. under the skin)
Trial: NCT02935725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00778596
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
Trial: NCT00778596
Drug: Placebo priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
Trial: NCT00113100
Drug: Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00253084
Drug: CD-LD IR
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
Trial: NCT00697697
Drug: 0.135mg MAP0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Trial: NCT00697697
Drug: 0.25mg MAP0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Trial: NCT00037830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice per day subcutaneous injection, equal volume as active drug
Trial: NCT01153321
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Oral dose od
Trial: NCT01153321
Drug: AZD2423 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose od
Trial: NCT00457860
Drug: Immunotoxin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089921
Drug: SCIO-469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg capsule three times daily for 12 weeks
Trial: NCT00089921
Drug: SCIO-469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg capsule three times daily for 12 weeks
Trial: NCT00089921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules three times daily and one tablet daily
Trial: NCT00089921
Drug: SCIO-469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet once daily for 12 weeks
Trial: NCT02147899
Drug: SYM-1219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02147899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00559910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00900627
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Oral bid
Trial: NCT00800553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg of placebo for approx. 2 weeks
Trial: NCT03597893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasally administrated
Trial: NCT04510090
Drug: EP547
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EP547
Trial: NCT04510090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03428529
Drug: Capecitabine Oral Product
RxNorm normalized name: capecitabine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Capecitabine concomitant to external beam radiotherapy
Trial: NCT03428529
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
Trial: NCT01405833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose IV matched placebo
Trial: NCT00002768
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
Trial: NCT00643760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00643760
Drug: GEn 1200mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin enacarbil 1200mg/day
Trial: NCT00643760
Drug: GEn 2400mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin enacarbil 2400mg/day
Trial: NCT00643760
Drug: GEn 3600mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin enacarbil 3600mg/day
Trial: NCT01491022
Drug: Ampyra first, then Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg po bid for 4 weeks followed by placebo 4 weeks.
Trial: NCT01491022
Drug: placebo first, then Ampyra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03082508
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as per protocol
Trial: NCT02128646
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02974439
Drug: Norvasc Tablets 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
Trial: NCT04391998
Drug: Iron Supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet twice daily after meals
Trial: NCT00280423
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02741323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability.
Trial: NCT01549691
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given night before surgery and at awakening, the day of surgery
Trial: NCT01637948
Drug: Listerine mouthrinse
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For six months
Trial: NCT00414869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive powder matching NCX-1000
Trial: NCT02683109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01451827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT00620282
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
Trial: NCT01579500
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of normal saline
Trial: NCT00831129
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg daily
Trial: NCT00707759
Drug: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d
Trial: NCT01038739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g per day
Trial: NCT02987699
Drug: 5-Fu, oxaliplatin , leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
Trial: NCT02160236
Drug: dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
Trial: NCT02987699
Drug: 5-Fu, oxaliplatin , leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
Trial: NCT02987699
Drug: 5-Fu, oxaliplatin , leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
Trial: NCT03796962
Drug: XEN1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT03192657
Drug: Calcineurin Inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
Trial: NCT03192657
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of steroid can be adjusted according to personal experience of the researcher.
Trial: NCT03013400
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is identical in appearance to the ebselen capsules
Trial: NCT00003537
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT04020536
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
Trial: NCT03760445
Drug: HDM201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg and 10mg capsules, given orally
Trial: NCT03760445
Drug: anthracycline
RxNorm normalized name: Anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg or other strength as locally available given intravenously
Trial: NCT03656952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching PF-06700841
Trial: NCT02907567
Drug: CT1812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active study drug
Trial: NCT02907567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active study drug
Trial: NCT01450813
Drug: Saline 0.06 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion x1 prior to laryngoscopy
Trial: NCT00589121
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
Trial: NCT00653523
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily
Trial: NCT00856037
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01625338
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF 400 mg tablet administered orally once daily
Trial: NCT00737100
Drug: Placebo Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to receive placebo matching active drug once daily
Trial: NCT00580957
Drug: Blocked
RxNorm normalized name: Strepsils Sore Throat and Blocked Nose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
Trial: NCT00580957
Drug: Intact
RxNorm normalized name: Intact parathyrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
Trial: NCT04023396
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
Trial: NCT01760655
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV